tras-TOOZ-oo-mab - pkrb
CardiomyopathyAdministration of trastuzumab products can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with trastuzumab-pkrb. Discontinue trastuzumab-pkrb treatment in patients receiving adjuvant therapy and withhold trastuzumab-pkrb in patients with metastatic disease for clinically significant decrease in left ventricular function.Infusion Reactions, Pulmonary ToxicityAdministration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt trastuzumab-pkrb infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue trastuzumab-pkrb for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.Embryo-Fetal ToxicityExposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception .
Medically reviewed by Drugs.com. Last updated on Oct 12, 2019.
Commonly used brand name(s)
In the U.S.
Pharmacologic Class: Trastuzumab
Uses for trastuzumab-pkrb
Trastuzumab-pkrb injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or docetaxel and carboplatin) or used alone following anthracycline-based therapy to treat HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab-pkrb injection is also used to treat HER2-overexpressing metastatic (cancer that has spread) breast cancer in patients who have received one or more chemotherapy treatments. It is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab-pkrb injection is also used together with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (stomach or esophagus cancer) in patients who have not received treatment previously.
Trastuzumab-pkrb prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab-pkrb is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-pkrb, other effects will also occur. Some of these may be serious and must be reported to your doctor.
Trastuzumab-pkrb is to be given only by or under the direct supervision of your doctor.
Before using trastuzumab-pkrb
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For trastuzumab-pkrb, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to trastuzumab-pkrb or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of trastuzumab-pkrb injection in the pediatric population. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of trastuzumab-pkrb injection in the elderly. However, elderly patients are more likely to have age-related heart problems, which may require caution in patients receiving trastuzumab-pkrb.
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving trastuzumab-pkrb, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using trastuzumab-pkrb with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Daunorubicin Citrate Liposome
- Daunorubicin Liposome
- Doxorubicin Hydrochloride Liposome
Using trastuzumab-pkrb with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Interactions with food/tobacco/alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
Other medical problems
The presence of other medical problems may affect the use of trastuzumab-pkrb. Make sure you tell your doctor if you have any other medical problems, especially:
- Congestive heart failure or
- Heart disease (eg, cardiomyopathy) or
- Heart rhythm problems (eg, arrhythmia) or
- Hypertension (high blood pressure) or
- Lung disease (eg, interstitial pneumonitis, pulmonary fibrosis, tumor)—Use with caution. May make these conditions worse.
Proper use of trastuzumab-pkrb
Medicines used to treat cancer are very strong and can have many side effects. Before receiving trastuzumab-pkrb, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.
A doctor or other trained health professional will give you trastuzumab-pkrb in a medical facility. It is given through a needle placed into one of your veins. It must be given slowly, so the needle should remain in place for at least 30 to 90 minutes.
Precautions while using trastuzumab-pkrb
It is very important that your doctor check your progress at regular visits to make sure that trastuzumab-pkrb is working properly. Blood and urine tests may be needed to check for unwanted effects.
Receiving trastuzumab-pkrb while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant during treatment with trastuzumab-pkrb and for 7 months after the last dose. If you think you have become pregnant while receiving the medicine, tell your doctor right away.
Your doctor may test your heart before you start receiving trastuzumab-pkrb injection and while you are getting treatments with trastuzumab-pkrb. Contact your doctor right away if you experience any chest pain, increased coughing, trouble with breathing, a sudden difficulty with breathing at night, rapid weight gain, or abnormal swelling in your ankles or legs. These could be symptoms of a serious heart problem.
Trastuzumab-pkrb may cause infusion reactions, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you start to have a fever, chills or shaking, dizziness, trouble breathing, itching or rash, or lightheadedness or fainting after receiving trastuzumab-pkrb.
Serious lung or breathing problems may occur after you receive trastuzumab-pkrb. Call your doctor right away if have changes in your breathing, chest tightness, or any type of breathing problem.
Trastuzumab-pkrb can temporarily lower the number of some types of blood cells in your body. Because of this, you may bleed or get infections more easily. To help with these problems, avoid being near people who are sick or have infections. Wash your hands often. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.
Do not receive an anthracycline medicine for up to 7 months after stopping treatment with medicines containing trastuzumab.
Trastuzumab-pkrb side effects
Check with your doctor or nurse immediately if any of the following side effects occur:
- Back pain
- black, tarry stools
- body aches or pain
- chest discomfort or pain
- decreased urine output
- difficulty breathing
- dilated neck veins
- dryness or soreness of the throat
- extreme tiredness or weakness
- fainting fast, irregular, or pounding heartbeat
- feeling of warmth
- general feeling of discomfort or illness
- irregular breathing
- joint pain
- loss of appetite
- lower back or side pain
- muscle aches and pains
- pain or tenderness around the eyes and cheekbones
- painful or difficult urination
- pale skin
- redness of the face, neck, arms, and occasionally, the upper chest
- skin rash
- sore throat
- stuffy or runny nose
- swelling of the face, fingers, feet, or lower legs
- tender, swollen glands in the neck
- tightness in the chest
- trouble in swallowing
- trouble sleeping
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- voice changes
- weight gain
- Bladder pain
- bloody or cloudy urine
- burning or stinging of the skin
- frequent urge to urinate
- hives, itching
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area
- tingling of the hands or feet
- unusual weight gain or loss
Incidence not known
- Bleeding gums
- numbness or tingling in the face, arms, or legs
- pinpoint red spots on the skin
- vision problems
- Bone pain
- difficulty in moving
- lack or loss of strength
- loss of appetite
- muscle stiffness
- stomach pain
Copyright 2020 Truven Health Analytics, Inc. All Rights Reserved.
- What is the difference between Ogivri and Herceptin?
- How many biosimilars have been approved in the United States?
More about trastuzumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 7 Reviews
- Drug class: HER2 inhibitors
- Trastuzumab Injection (Intravenous)
- ... +6 more